GlassScriptPhysician profile
John J Robbins
NPI 1952350415
$26,033.42
in general payments reported to CMS, 2019-2025
75 companies · $6,498 in 2025
The $6,498 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,508 · 2022: $5,268 · 2023: $4,518 · 2024: $5,242 · 2025: $6,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $1,036 · Education: $237 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,835.07 |
| Travel and Lodging | $1,035.77 |
| Education | $236.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,467.33 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,232.08 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Livanova USA, INC. | $1,584.51 | 2021-2025 | Vns Therapy |
| Ucb, INC. | $1,491.47 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $1,405.11 | 2021-2025 | Xcopri |
| Neurocrine Biosciences, INC. | $1,354.70 | 2021-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,231.92 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Acadia Pharmaceuticals INC | $1,060.29 | 2021-2025 | Nuplazid |
| Neurelis, INC. | $1,026.84 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $659.71 | 2021-2025 | |
| Pfizer INC. | $655.93 | 2023-2025 | |
| Argenx US, INC. | $636.13 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $541.19 | 2022 | |
| Mdd US Operations, LLC | $516.96 | 2021-2025 | Gocovri, Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $493.04 | 2023-2025 | Hyqvia, Gammagard |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.63 | 2021-2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $481.73 | 2021-2025 | Acthar |
| Eisai INC. | $481.45 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $461.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $422.73 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $362.80 | 2022-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $342.76 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $331.78 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Impel Pharmaceuticals INC. | $309.17 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $304.64 | 2021 | |
| Alexion Pharmaceuticals, INC. | $282.35 | 2021-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $271.49 | 2021-2025 | Qelbree |
| Azurity Pharmaceuticals, INC. | $254.33 | 2023-2025 | Horizant, Horizant |
| Amneal Pharmaceuticals LLC | $239.34 | 2021-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Genzyme Corporation | $207.17 | 2022-2025 | |
| Kyowa Kirin, INC. | $205.82 | 2021-2025 | Nourianz |
| Harmony Biosciences LLC | $203.30 | 2024 | |
| Adamas Pharmaceuticals, INC. | $189.82 | 2021 | |
| Emd Serono, INC. | $182.92 | 2022-2024 | Mavenclad |
| Allergan, INC. | $178.83 | 2021 | |
| Greenwich Biosciences, INC. | $161.36 | 2021 | |
| Corium, LLC | $158.75 | 2022-2023 | Adlarity |
| Acorda Therapeutics, INC | $144.44 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $140.95 | 2021-2025 | Xeomin |
| Impel Pharmaceuticals LLC | $131.46 | 2024-2025 | Trudhesa |
| Sumitomo Pharma America, INC. | $101.04 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $92.58 | 2023-2025 | Symbravo, Sunosi |
| Medtronic, INC. | $83.85 | 2025 | Inceptiv |
| Astrazeneca Pharmaceuticals LP | $80.51 | 2025 | Wainua |
| Avanir Pharmaceuticals, INC. | $78.24 | 2021-2022 | |
| Avion Pharmaceuticals | $78.02 | 2022-2023 | Dhivy |
| Janssen Biotech, INC. | $74.87 | 2025 | |
| Banner Life Sciences, LLC | $73.60 | 2022-2024 | |
| Lundbeck LLC | $71.82 | 2021-2024 | Rexulti, Vyepti |
| Grifols USA, LLC | $70.76 | 2022-2025 | Gamunex-C |
| Vanda Pharmaceuticals INC. | $67.41 | 2025 | Ponvory |
| Collegium Pharmaceutical, INC. | $63.74 | 2021-2023 | Xtampza |
| Janssen Pharmaceuticals, INC | $57.27 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $52.84 | 2021 | |
| Grt US Holding, INC. | $52.57 | 2022 | |
| Csl Behring | $49.09 | 2021-2024 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $48.95 | 2021 | |
| Boston Scientific Corporation | $45.77 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $45.26 | 2024 | |
| Genentech USA, INC. | $41.35 | 2025 | Ocrevus Zunovo |
| Tg Therapeutics, INC. | $40.86 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $40.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $38.41 | 2023-2025 | Rexulti, Nuedexta |
| Horizon Therapeutics Plc | $36.26 | 2022-2023 | Uplizna |
| Tonix Medicines, INC. | $34.99 | 2025 | Zembrace Symtouch |
| Aquestive Therapeutics, INC. | $30.15 | 2021-2022 | |
| Abbott Laboratories | $29.66 | 2022-2023 | Proclaim |
| Arbor Pharmaceuticals, INC. | $28.79 | 2021 | |
| Cycle Pharmaceuticals INC | $24.37 | 2024 | Tascenso Odt |
| Amicus Therapeutics, INC. | $19.72 | 2022 | |
| Microtransponder, INC. | $19.13 | 2025 | |
| Scilex Pharmaceuticals INC. | $17.89 | 2023 | Ztlido |
| Idorsia Pharmaceuticals US INC | $17.27 | 2023 | Quviviq |
| Ge Healthcare | $15.45 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.